Concordance between the chang and the International Society of Pediatric Oncology (SIOP) ototoxicity grading scales in patients treated with cisplatin for medulloblastoma

Reporting ototoxicity is frequently complicated by use of various ototoxicity criteria. The International Society of Pediatric Oncology (SIOP) ototoxicity grading scale was recently proposed for standardized use in reporting hearing loss outcomes across institutions. The aim of this study was to evaluate the concordance between the Chang and SIOP ototoxicity grading scales. Differences between the two scales were identified and the implications these differences may have in the clinical setting were discussed.

[1]  P. Steyger,et al.  Platinum-induced ototoxicity in children: a consensus review on mechanisms, predisposition, and protection, including a new International Society of Pediatric Oncology Boston ototoxicity scale. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  K. W. Chang,et al.  Clinically accurate assessment and grading of ototoxicity , 2011, The Laryngoscope.

[3]  Kay W Chang,et al.  Practical grading system for evaluating cisplatin ototoxicity in children. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  E. Neuwelt,et al.  Critical need for international consensus on ototoxicity assessment criteria. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  J. Panetta,et al.  Clinical Pharmacokinetics of Amifostine and WR1065 in Pediatric Patients with Medulloblastoma , 2010, Clinical Cancer Research.

[6]  B. Fligor,et al.  Ototoxicity in children treated for osteosarcoma , 2009, Pediatric blood & cancer.

[7]  T. Merchant,et al.  Amifostine protects against cisplatin-induced ototoxicity in children with average-risk medulloblastoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  T. Merchant,et al.  Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicentre trial. , 2006, The Lancet. Oncology.

[9]  M. Kris,et al.  Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  J. Wee,et al.  Sensorineural hearing loss after radiotherapy and chemoradiotherapy: a single, blinded, randomized study. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  K. Knight,et al.  Ototoxicity in children receiving platinum chemotherapy: underestimating a commonly occurring toxicity that may influence academic and social development. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  J. Silber,et al.  Predicting cisplatin ototoxicity in children: the influence of age and the cumulative dose. , 2004, European journal of cancer.

[13]  Mary Pat Moeller,et al.  The importance of high-frequency audibility in the speech and language development of children with hearing loss. , 2004, Archives of otolaryngology--head & neck surgery.

[14]  K. Mattucci,et al.  A Proposed Protocol for Monitoring Ototoxicity in Patients who Take Cochleo- or Vestibulotoxic Drugs , 2003, Ear, nose, & throat journal.

[15]  J. Henry,et al.  An efficient test protocol for identification of a limited, sensitive frequency test range for early detection of ototoxicity. , 2002, Journal of rehabilitation research and development.

[16]  Ning Li,et al.  Basic Statistics and Pharmaceutical Statistical Applications , 2000 .

[17]  C. Yoshinaga-Itano,et al.  Benefits of early intervention for children with hearing loss. , 1999, Otolaryngologic clinics of North America.

[18]  C. Yoshinaga-Itano,et al.  The efficacy of early identification and intervention for children with hearing impairment. , 1999, Pediatric clinics of North America.

[19]  Christine Yoshinaga-Itano,et al.  Language of Early- and Later-identified Children With Hearing Loss , 1998, Pediatrics.

[20]  R. Parker,et al.  Children with Minimal Sensorineural Hearing Loss: Prevalence, Educational Performance, and Functional Status , 1998, Ear and hearing.

[21]  R H Wilson,et al.  High‐Frequency Audiometric Monitoring Strategies for Early Detection of Ototoxicity , 1994, Ear and hearing.

[22]  J. Durrant,et al.  Audiologic monitoring for ototoxicity. , 1993, Otolaryngologic clinics of North America.

[23]  B. Blakley,et al.  Patterns of Hearing Loss Resulting from cis-Platinum Therapy , 1993, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.

[24]  J. Henry,et al.  High-frequency monitoring for early detection of cisplatin ototoxicity. , 1993, Archives of otolaryngology--head & neck surgery.

[25]  C. R. Pinkerton,et al.  Cisplatin ototoxicity in children: a practical grading system. , 1991, Medical and pediatric oncology.

[26]  R A Bentler,et al.  Effects of mild and moderate hearing impairments on language, educational, and psychosocial behavior of children. , 1986, The Journal of speech and hearing disorders.